Phase 3 Readout
AKBA: Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vada
August 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 1, 2026
- Company
- Akebia Therapeutics, Inc. (AKBA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vada
- Indication
- Anemia of Chronic Kidney Disease